본문 바로가기
KERD
논문KCI 등재

AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines—A Systematic Review

MM Samim|Debjyoti Dhar|Sheetal Goyal|Treshita Dey|Naznin Parvin|Rutul D. Shah|Vikram Singh|Sampurna Chowdhury|Bhavesh Mohan Lal|Nibu Varghese|Abhishek Gohel|Abhishek Chowdhury|Aritra Chatterjee|Shahyan Siddiqui
대한신경과학회 (Korean Neurological Association)|2022.11|Journal of Clinical Neurology|제18권 제6호|pp. 692-710

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19COVID-19 vaccineautoimmune encephalitispostinfectious encephalitis

초록

Background and Purpose Autoimmune encephalitis (AIE) following coronavirus disease 2019 (COVID-19) is an underexplored condition. This study aims to systematically review the clinico-investigational and pathophysiologic aspects of COVID-19 and its vaccines in association with AIE, and identify the factors predicting neurological severity and outcomes. Methods Relevant data sources were searched using appropriate search terms on January 15, 2022. Studies meeting the criteria for AIE having a temporal association with COVID-19 or its vaccines were included. Results Out of 1,894 citations, we included 61 articles comprising 88 cases: 71 of COVID-19-associated AIE, 3 of possible Bickerstaff encephalitis, and 14 of vaccine-associated AIE.There were 23 definite and 48 possible seronegative AIE cases. Anti-NMDAR (N-methyl-D-aspartate receptor; n=12, 16.9%) was the most common definite AIE. Males were more commonly affected (sex ratio=1.63) in the AIE subgroup. The neurological symptoms included alteredmental state (n=53, 74.6%), movement disorders (n=28, 39.4%), seizures (n=24, 33.8%), behavioural (n=25, 35.2%), and speech disturbances (n=17, 23.9%). The median latency to AIE diagnosis was 14 days (interquartile range=4–22 days). Female sex and ICU admission had higherrisks of sequelae, with odds ratio (OR) of 2.925 (95% confidence interval [CI]=1.005–8.516)and 3.515 (95% CI=1.160–10.650), respectively. Good immunotherapy response was seen in42/48 (87.5%) and 13/13 (100%) of COVID-19-associated and vaccine-associated AIE patients, respectively. Sequelae were reported in 22/60 (36.7%) COVID-19 associated and 10/13 (76.9%) vaccine-associated cases. Conclusions The study has revealed diagnostic, therapeutic, and pathophysiological aspects of AIE associated with COVID-19 and its vaccines, and its differences from postinfectious AIE.

Abstract

Background and Purpose Autoimmune encephalitis (AIE) following coronavirus disease 2019 (COVID-19) is an underexplored condition. This study aims to systematically review the clinico-investigational and pathophysiologic aspects of COVID-19 and its vaccines in association with AIE, and identify the factors predicting neurological severity and outcomes. Methods Relevant data sources were searched using appropriate search terms on January 15, 2022. Studies meeting the criteria for AIE having a temporal association with COVID-19 or its vaccines were included. Results Out of 1,894 citations, we included 61 articles comprising 88 cases: 71 of COVID-19-associated AIE, 3 of possible Bickerstaff encephalitis, and 14 of vaccine-associated AIE.There were 23 definite and 48 possible seronegative AIE cases. Anti-NMDAR (N-methyl-D-aspartate receptor; n=12, 16.9%) was the most common definite AIE. Males were more commonly affected (sex ratio=1.63) in the AIE subgroup. The neurological symptoms included alteredmental state (n=53, 74.6%), movement disorders (n=28, 39.4%), seizures (n=24, 33.8%), behavioural (n=25, 35.2%), and speech disturbances (n=17, 23.9%). The median latency to AIE diagnosis was 14 days (interquartile range=4–22 days). Female sex and ICU admission had higherrisks of sequelae, with odds ratio (OR) of 2.925 (95% confidence interval [CI]=1.005–8.516)and 3.515 (95% CI=1.160–10.650), respectively. Good immunotherapy response was seen in42/48 (87.5%) and 13/13 (100%) of COVID-19-associated and vaccine-associated AIE patients, respectively. Sequelae were reported in 22/60 (36.7%) COVID-19 associated and 10/13 (76.9%) vaccine-associated cases. Conclusions The study has revealed diagnostic, therapeutic, and pathophysiological aspects of AIE associated with COVID-19 and its vaccines, and its differences from postinfectious AIE.

참고문헌 (137)

  1. Misra S, "Frequency of neurologic manifestations in COVID-19 : a systematic review and meta-analysis", Neurology, 97, pp.e2269~e2281 (2021)
  2. Ellul MA, "Neurological associations of COVID-19", Lancet Neurol, 19, pp.767~783 (2020)
  3. Dhar D, "Systemic inflammatory syndrome in COVID-19-SISCoV study : systematic review and meta-analysis", Pediatr Res (2021)[DOI]
  4. Payus AO, "Immune-mediated neurological syndrome in SARS-CoV-2 infection : a review of literature on autoimmune encephalitis in COVID-19", Neurol Sci, 43, pp.1533~1547 (2021)
  5. Valencia Sanchez C, "Autoimmune encephalitis after SARS-CoV-2 infection : case frequency, findings, and outcomes", Neurology, 97, pp.e2262~e2268 (2021)
  6. Cao A, "Severe COVID-19-related encephalitis can respond to immunotherapy", Brain, 143, pp.e102~ (2020)
  7. Paterson RW, "The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings", Brain, 143, pp.3104~3120 (2020)
  8. Abboud H, "Autoimmune encephalitis : proposed best practice recommendations for diagnosis and acute management", J Neurol Neurosurg Psychiatry, 92, pp.757~768 (2021)
  9. Graus F, "A clinical approach to diagnosis of autoimmune encephalitis", Lancet Neurol, 15, pp.391~404 (2016)
  10. Armangue T, "Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis : a prospective observational study and retrospective analysis", Lancet Neurol, 17, pp.760~772 (2018)
  11. Nosadini M, "Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis : a systematic literature review with analysis of 43cases", Dev Med Child Neurol, 59, pp.796~805 (2017)
  12. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, "A minimal common outcome measure set for COVID-19 clinical research", Lancet Infect Dis, 20, pp.e192~e197 (2020)
  13. Munn Z, "Methodological quality of case series studies : an introduction to the JBI critical appraisal tool", JBI Evid Synth, 18, pp.2127~2133 (2020)
  14. "Study quality assessment tools"[URL]
  15. Ayatollahi P, "Possible autoimmune encephalitis with claustrum sign in case of acute SARS-CoV-2 infection", Can J Neurol Sci, 48, pp.430~432 (2021)
  16. Llorente Ayuso L, "Bickerstaffencephalitis after COVID-19", J Neurol, 268, pp.2035~2037 (2021)
  17. Burr T, "N-methyl-d-aspartate receptor encephalitis associated with COVID-19 infection in a toddler", Pediatr Neurol, 114, pp.75~76 (2021)
  18. Allahyari F, "A case report of simultaneous autoimmune and COVID-19 encephalitis", J Neurovirol, 27, pp.504~506 (2021)
  19. Panariello A, "Anti-NMDA receptor encephalitis in a psychiatric Covid-19patient : a case report", Brain Behav Immun, 87, pp.179~181 (2020)
  20. Jeanneret V, "Post-infectious rhombencephalitis after coronavirus-19 infection : a case report and literature review", J Neuroimmunol, 357, pp.577623~ (2021)
  21. Zambreanu L, "A case of limbic encephalitis associated with asymptomatic COVID-19 infection", J Neurol Neurosurg Psychiatry, 91, pp.1229~1230 (2020)
  22. Pizzanelli C, "Autoimmune limbic encephalitis related to SARS-CoV-2 infection : case-report and review of the literature", Brain Behav Immun Health, 12, pp.100210~ (2021)
  23. Monti G, "Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19", Seizure, 81, pp.18~20 (2020)
  24. Mulder J, "Autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with Covid-19", Am J Psychiatry, 178, pp.485~489 (2021)
  25. Parnasa E, "Autoimmune encephalitis secondary to COVID-19 infection", Isr Med Assoc J, 23, pp.335~ (2021)
  26. Sarigecili E, "Pediatric anti-NMDA receptor encephalitis associated with COVID-19", Childs Nerv Syst, 37, pp.3919~3922 (2021)
  27. McHattie AW, "Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19", J Neurol, 268, pp.3995~3997 (2021)
  28. Sánchez-Morales AE, "Neurological manifestations temporally associated with SARS-CoV-2infection in pediatric patients in Mexico", Childs Nerv Syst, 37, pp.2305~2312 (2021)
  29. Hosseini AA, "Delirium as a presenting feature in COVID-19 : neuroinvasive infection or autoimmune encephalopathy?", Brain Behav Immun, 88, pp.68~70 (2020)
  30. Kilic MA, "Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19 : Morvan syndrome", J Neurol, 268, pp.4492~4494 (2021)
  31. Yousuf F, "Autoimmune encephalitis following recovery of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection", Neurology, 96, pp.2756~ (2021)
  32. Gaughan M, "Pediatric parainfectious encephalitis associated with COVID-19", Neurology, 96, pp.541~544 (2021)
  33. Moideen S, "Psychosis in a patient with anti-NMDA-receptor antibodies experiencing significant stress related to COVID-19", Brain Behav Immun Health, 7, pp.100125~ (2020)
  34. Asan L, "Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19 : a case report", Ther Adv Neurol Disord, 14, pp.17562864211062824~ (2021)
  35. Valadez-Calderon J, "Co-expression of anti-NMDAR and anti-GAD65 antibodies. A case of autoimmune encephalitis in a post-COVID-19 patient", Neurologia (2021)
  36. Dono F, "New-onset refractory status epilepticus(NORSE)in post SARS-CoV-2 autoimmune encephalitis : a case report", Neurol Sci, 42, pp.35~38 (2021)
  37. Álvarez Bravo G, "Anti-NMDA receptor encephalitis secondary to SARS-CoV-2 infection", Neurologia(Engl Ed), 35, pp.699~700 (2020)
  38. Bhagat R, "New-onset seizure with possible limbic encephalitis in a patient with COVID-19 infection : a case report and review", J Investig Med High Impact Case Rep, 9, pp.2324709620986302~ (2021)
  39. Smyth D, "Post-COVID-19 opsoclonus-myoclonus syndrome and encephalopathy associated with leucine-rich glioma-inactivated 1(LGI-1)antibodies", J Neurol Sci, 430, pp.119982~ (2021)
  40. Vandervorst F, "Encephalitis associated with the SARS-CoV-2 virus : a case report", Interdiscip Neurosurg, 22, pp.100821~ (2020)
  41. Kahwagi J, "about one pediatric observation and review of the literature", Rev Neurol(Paris), 177, pp.132~134 (2021)
  42. Le Guennec L, "Orbitofrontal involvement in a neuroCOVID-19 patient", Epilepsia, 61, pp.e90~e94 (2020)
  43. Urso L, "The case of encephalitis in a COVID-19 pediatric patient", Neurol Sci, 43, pp.105~112 (2022)
  44. Manganotti P, "Intravenous immunoglobulin response in new-onset refractory status epilepticus(NORSE)COVID-19 adult patients", J Neurol, 268, pp.3569~3573 (2021)
  45. Al-Mashdali AF, "Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone:a case report", Ann Med Surg(Lond), 69, pp.102803~ (2021)
  46. Takata J, "A case report of ChAdOx1 nCoV-19 vaccine–associated encephalitis", BMC Neurol, 21, pp.485~ (2021)
  47. 신혜림, "Autoimmune Encephalitis as an Adverse Event of COVID-19 Vaccination", Journal of Clinical Neurology, 18(1), pp.114~116 (2022), 대한신경과학회
  48. Kwon H, "Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination", Neurol Sci, 43, pp.1487~1489 (2021)
  49. Flannery P, "Acute psychosis due to anti-N-methyl D-aspartate receptor encephalitis following COVID-19 vaccination : a case report", Front Neurol, 12, pp.764197~ (2021)
  50. Kaulen LD, "Neurological autoimmune diseases following vaccinations against SARS-CoV-2 : a case series", Eur J Neurol, 29, pp.555~563 (2021)
  51. Walter A, "A neurologist’s rhombencephalitis after comirnaty vaccination. A change of perspective", Neurol Res Pract, 3, pp.56~ (2021)
  52. Torrealba-Acosta G, "Acute encephalitis, myoclonus and sweet syndrome after mRNA-1273 vaccine", BMJ Case Rep, 14, pp.e243173~ (2021)
  53. Gunawardhana C, "Delayed presentation of postinfectious encephalitis associated with SARS-CoV-2 infection : a case report", Neurol Sci, 42, pp.3527~3530 (2021)
  54. Hara M, "COVID-19 post-infectious encephalitis presenting with delirium as an initial manifestation", J Investig Med High Impact Case Rep, 9, pp.23247096211029787~ (2021)
  55. El-Zein RS, "COVID-19-associated meningoencephalitis treated with intravenous immunoglobulin", BMJ Case Rep, 13, pp.e237364~ (2020)
  56. Ishaq H, "Post-COVID opsoclonus myoclonus syndrome : a case report from Pakistan", Front Neurol, 12, pp.672524~ (2021)
  57. Beretta S, "COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease", Ann Clin Transl Neurol, 8, pp.2314~2318 (2021)
  58. Oosthuizen K, "SARS-CoV-2 encephalitis presenting as a clinical cerebellar syndrome : a case report", Neurology, 97, pp.27~29 (2021)
  59. Zuhorn F, "Parainfectious encephalitis in COVID-19 : "The Claustrum Sign"", J Neurol, 268, pp.2031~2034 (2021)
  60. Freire-Álvarez E, "COVID-19-associated encephalitis successfully treated with combination therapy", Clin Infect Pract, 7, pp.100053~ (2020)
  61. Afshar H, "Evolution and resolution of brain involvement associated with SARS-CoV2 infection : a close clinical-paraclinical follow up study of a case", Mult Scler Relat Disord, 43, pp.102216~ (2020)
  62. Ariza-Varón M, "Psychosis associated with suspected SARS-CoV-2 encephalitis with response to steroids: a case report", Infect Dis(Lond), 54, pp.152~156 (2022)
  63. Khoo A, "Postinfectious brainstem encephalitis associated with SARS-CoV-2", J Neurol Neurosurg Psychiatry, 91, pp.1013~1014 (2020)
  64. Zlotnik Y, "Case report : anti-LGI1 encephalitis following COVID-19 vaccination", Front Immunol, 12, pp.813487~ (2022)
  65. Fan HT, "COVID-19 vaccine-induced encephalitis and status epilepticus", QJM, 115, pp.91~93 (2022)
  66. Solís Tarazona LR, "Post-SARS-CoV-2-vaccine autoimmune encephalitis : a case report", SVOA Neurology, 2, pp.155~157 (2021)
  67. Delorme C, "COVID-19-related encephalopathy : a case series with brain FDG-positron-emission tomography", computed tomography findings, 2020, pp.27, 2651~2657
  68. Pilotto A, "Clinical presentation and outcomes of severe acute respiratory syndrome coronavirus 2–related encephalitis : the ENCOVID multicenter study", J Infect Dis, 223, pp.28~37 (2021)
  69. Franke C, "High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms", Brain Behav Immun, 93, pp.415~419 (2021)
  70. Kremer S, "Neurologic and neuroimaging findings in patients with COVID-19 : a retrospective multicenter study", Neurology, 95, pp.e1868~e1882 (2020)
  71. Guilmot A, "Immune-mediated neurological syndromes in SARS-CoV-2-infected patients", J Neurol, 268, pp.751~757 (2021)
  72. Zuhorn F, "Postvaccinal encephalitis after ChAdOx1 nCov-19", Ann Neurol, 90, pp.506~511 (2021)
  73. Benameur K, "Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020", Emerg Infect Dis, 26, pp.2016~2021 (2020)
  74. Armangue T, "Autoimmune encephalitis as differential diagnosis of infectious encephalitis", Curr Opin Neurol, 27, pp.361~368 (2014)
  75. Ramanathan S, "Autoimmune encephalitis : recent updates and emerging challenges", J Clin Neurosci, 21, pp.722~730 (2014)
  76. Armangue T, "Autoimmune post-herpes simplex encephalitis of adults and teenagers", Neurology, 85, pp.1736~1743 (2015)
  77. Hofmann C, "Anti-NMDA receptor encephalitis after TdaP-IPV booster vaccination : cause or coincidence?", J Neurol, 258, pp.500~501 (2011)
  78. Dalmau J, "Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis", Lancet Neurol, 10, pp.63~74 (2011)
  79. Wang H, "Anti-NMDA receptor encephalitis and vaccination", Int J Mol Sci, 18, pp.193~ (2017)
  80. Guedes BF, "Potential autoimmune encephalitis following yellow fever vaccination : a report of three cases", J Neuroimmunol, 355, pp.577548~ (2021)
  81. Dalmau J, "Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies", Lancet Neurol, 7, pp.1091~1098 (2008)
  82. Barry H, "Anti-N-methyl-d-aspartate receptor encephalitis : review of clinical presentation, diagnosis and treatment", BJPsych Bull, 39, pp.19~23 (2015)
  83. Saraya AW, "Differences and diversity of autoimmune encephalitis in 77 cases from a single tertiary care center", BMC Neurol, 19, pp.273~ (2019)
  84. 이상보, "Clinical Features and Treatment Outcomes of Seronegative Pediatric Autoimmune Encephalitis", Journal of Clinical Neurology, 17(2), pp.300~306 (2021), 대한신경과학회
  85. Pradhan S, "Antibody negative autoimmune encephalitis-Does it differ from definite one?", Ann Indian Acad Neurol, 22, pp.401~408 (2019)
  86. Dotan A, "The SARS-CoV-2 as an instrumental trigger of autoimmunity", Autoimmun Rev, 20, pp.102792~ (2021)
  87. Diamond MS, "Innate immunity : the first line of defense against SARS-CoV-2", Nat Immunol, 23, pp.165~176 (2022)
  88. Wang K, "CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells", Signal Transduct Target Ther, 5, pp.283~ (2020)
  89. Qiao J, "The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2in human and mouse brain cells and mouse brain tissues", Biochem Biophys Res Commun, 533, pp.867~871 (2020)
  90. Cantuti-Castelvetri L, "Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity", Science, 370, pp.856~860 (2020)
  91. Mayi BS, "The role of neuropilin-1 in COVID-19", PLoS Pathog, 17, pp.e1009153~ (2021)
  92. Zipeto D, "ACE2", ADAM17, Front Immunol, pp.2020, 11[DOI]
  93. Schreiber B, "Shedding light on COVID-19 : ADAM17 the missing link?", Am J Ther, 28, pp.e358~e360 (2020)
  94. Solerte SB, "Dipeptidyl peptidase-4(DPP4)inhibition in COVID-19", Acta Diabetol, 57, pp.779~783 (2020)
  95. Bassendine MF, "COVID-19 and comorbidities : a role for dipeptidyl peptidase 4(DPP4)in disease severity?", J Diabetes, 12, pp.649~658 (2020)
  96. de Sousa AK, "SARSCoV-2-mediated encephalitis : role of AT2R receptors in the bloodbrain barrier", Med Hypotheses, 144, pp.110213~ (2020)
  97. Qi F, "Single cell RNA sequencing of 13human tissues identify cell types and receptors of human coronaviruses", Biochem Biophys Res Commun, 526, pp.135~140 (2020)
  98. Padmanabhan P, "Targeting TMPRSS2 and Cathepsin B", L together may be synergistic against SARS-CoV-2 infection, 2020, pp.16, e1008461~
  99. Coutard B, "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade", Antiviral Res, 176, pp.104742~ (2020)
  100. Dando SJ, "Pathogens penetrating the central nervous system : infection pathways and the cellular and molecular mechanisms of invasion", Clin Microbiol Rev, 27, pp.691~726 (2014)
  101. Lauer AN, "The diverse cellular responses of the choroid plexus during infection of the central nervous system", Am J Physiol Cell Physiol, 314, pp.C152~C165 (2018)
  102. Proal AD, "Long COVID or post-acute sequelae of COVID-19(PASC) : an overview of biological factors that may contribute to persistent symptoms", Front Microbiol, 12, pp.698169~ (2021)
  103. Pezzini A, "Lifting the mask on neurological manifestations of COVID-19", Nat Rev Neurol, 16, pp.636~644 (2020)
  104. Desforges M, "Human coronaviruses and other respiratory viruses : underestimated opportunistic pathogens of the central nervous system?", Viruses, 12, pp.14~ (2019)
  105. McGavern DB, "Illuminating viral infections in the nervous system", Nat Rev Immunol, 11, pp.318~329 (2011)
  106. Pacheco-Herrero M, "Elucidating the neuropathologic mechanisms of SARS-CoV-2 infection", Front Neurol, 12, pp.660087~ (2021)
  107. Meinhardt J, "Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19", Nat Neurosci, 24, pp.168~175 (2021)
  108. Varga Z, "Endothelial cell infection and endotheliitis in COVID-19", Lancet, 395, pp.1417~1418 (2020)
  109. Yarlagadda A, "Blood-brain barrier : COVID-19, pandemics, and cytokine norms", Innov Clin Neurosci, 18, pp.21~23 (2021)
  110. Mahmudpour M, "COVID-19 cytokine storm : the anger of inflammation", Cytokine, 133, pp.155151~ (2020)
  111. Fu Y, "Understanding SARS-CoV-2-mediated inflammatory responses : from mechanisms to potential therapeutic tools", Virol Sin, 35, pp.266~271 (2020)
  112. Fu B, "Why tocilizumab could be an effective treatment for severe COVID-19?", J Transl Med, 18, pp.164~ (2020)
  113. Fung SY, "A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence : lessons from other pathogenic viruses", Emerg Microbes Infect, 9, pp.558~570 (2020)
  114. Najjar S, "Central nervous system complications associated with SARSCoV-2 infection : integrative concepts of pathophysiology and case reports", J Neuroinflammation, 17, pp.231~ (2020)
  115. Dantzer R, "Neuroimmune interactions : from the brain to the immune system and vice versa", Physiol Rev, 98, pp.477~504 (2018)
  116. Erickson MA, "Interactions of SARS-CoV-2 with the blood-brain barrier", Int J Mol Sci, 22, pp.2681~ (2021)
  117. Rhea EM, "The S1 protein of SARS-CoV-2 crosses the bloodbrain barrier in mice", Nat Neurosci, 24, pp.368~378 (2021)
  118. Altmayer V, "Endothelial cell biomarkers in critically ill COVID-19 patients with encephalitis", J Neurochem (2021)[DOI]
  119. Iadecola C, "Effects of COVID-19 on the nervous system", Cell, 183, pp.16~27 (2020)
  120. Panesar NS, "Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol", Eur J Clin Invest, 34, pp.382~384 (2004)
  121. Sun SH, "A mouse model of SARS-CoV-2 infection and pathogenesis", Cell Host Microbe, 28, pp.124~133 (2020)
  122. Ribeiro DE, "Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology", Mol Psychiatry, 26, pp.1044~1059 (2021)
  123. Clough E, "Mitochondrial dynamics in SARS-COV2 spike protein treated human microglia : implications for neuro-COVID", J Neuroimmune Pharmacol, 16, pp.770~784 (2021)
  124. Schwabenland M, "Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions", Immunity, 54, pp.1594~1610 (2021)
  125. Yang AC, "Dysregulation of brain and choroid plexus cell types in severe COVID-19", Nature, 595, pp.565~571 (2021)
  126. Wang L, "A human three-dimensional neural-perivascular ‘assembloid’promotes astrocytic development and enables modeling of SARSCoV-2 neuropathology", Nat Med, 27, pp.1600~1606 (2021)
  127. Matschke J, "Neuropathology of patients with COVID-19 in Germany : a post-mortem case series", Lancet Neurol, 19, pp.919~929 (2020)
  128. Bien CG, "Immunopathology of autoantibody-associated encephalitides : clues for pathogenesis", Brain, 135(Pt 5), pp.1622~1638 (2012)
  129. Dalmau J, "Antibody-mediated encephalitis", N Engl J Med, 378, pp.840~851 (2018)
  130. Hughes EG, "Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis", J Neurosci, 30, pp.5866~5875 (2010)
  131. Irani SR, "Antibodies to Kv1 potassium channel-complex proteins leucinerich, glioma inactivated 1 protein and contactin-associated protein-2in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia", Brain, 133, pp.2734~2748 (2010)
  132. Dalmau J, "Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system", Physiol Rev, 97, pp.839~887 (2017)
  133. Gordon DE, "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing", Nature, 583, pp.459~468 (2020)
  134. Vasilevska V, "Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases", J Neuroinflammation, 18, pp.245~ (2021)
  135. van Sonderen A, "Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4", Ann Neurol, 81, pp.193~198 (2017)
  136. Shu Y, "HLA class II allele DRB1*16 : 02 is associated with anti-NMDAR encephalitis", J Neurol Neurosurg Psychiatry, 90, pp.652~658 (2019)
  137. Dahm L, "Seroprevalence of autoantibodies against brain antigens in health and disease", Ann Neurol, 76, pp.82~94 (2014)

관련 논문AI추천

Outcome and Sequelae of Autoimmune EncephalitisAlexandra Mailles, Ariane Soldatos, Felicia C. Chow, James Sejvar, Jean-Paul Stahl, Kathryn A. Kvam, Pierre Tattevin대한신경과학회 · Journal of Clinical Neurology2024 · 제20권 제1호Autoimmune Encephalitis as an Adverse Event of COVID-19 Vaccination김백균, 김아련, 신혜림, 이순태대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제1호Clinical Features and Treatment Outcomes of Seronegative Pediatric Autoimmune Encephalitis강훈철, 김세희, 김흥동, 이상보, 이준수대한신경과학회 · Journal of Clinical Neurology2021 · 제17권 제2호Autoantibody Encephalitis: Presentation, Diagnosis, and ManagementEric Lancaster대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제4호Te Diagnosis and Treatment of Autoimmune EncephalitisEric Lancaster대한신경과학회 · Journal of Clinical Neurology2016 · 제12권 제1호Clinical Approach to Autoimmune Epilepsy강경욱, 김근태, 김대영, 김동욱, 노영주, 변정익, 서종근, 양광익, 이순태, 장윤혁, 조용원대한신경과학회 · Journal of Clinical Neurology2020 · 제16권 제4호

이 간행물의 다른 논문 (16건)

A Memorial Tribute to Kyoung-Min Lee: An Outstanding Behavioral Neurologist and Cognitive NeuroscientistEunbeen Lee, 허재혁, 전현애, Min-Jeong Kim, Soyoung Kang, 우성호, Hyeyeon Joo, Min-Hee Seo, Jeong-In Cha, Jeh-Kwang Ryupp. 603-609Vessel Wall Changes on Serial High-Resolution MRI and the Use of Cilostazol in Patients With Adult-Onset Moyamoya DiseaseJae Youn Kim, Hyung Jun Kim, Kwang Hyun Pan, Jong-Won Chung, Gyeong-Moon Kim, Tae Keun Jee, Je Young Yeon, Jong-Soo Kim, Seung-Chyul Hong, Jihoon Cha, Keon Ha Kim, 전평, Oh Young Bang, Woo-Keun Seo, 최은혁, 성민정pp. 610-618Resting Heart Rate and Cognitive Decline: A Meta-Analysis of Prospective Cohort StudiesHong-Bae Kim, 한현정, 정영희pp. 619-627Seborrheic Dermatitis Is Related to Motor Symptoms in Parkinson’s DiseaseZvonimir Popovic, Svetlana Tomic, Igor Kuric, Tihana Gilman Kuric, Jagoda Kragujevic, Tea Mirosevic Zubonja, Ines Rajkovaca, Sara Matosapp. 628-634Mammillary Body Atrophy in Temporal Lobe Epilepsy With Hippocampal SclerosisDongah Lee, 조규호, Ho-Joon Lee, 박강민pp. 635-641
원문 보기